FDA Faces “Conundrum” In Determining Efficacy Of Children’s Cold Products
This article was originally published in The Tan Sheet
Executive Summary
FDA Office of New Drugs Director John Jenkins is uncertain the efficacy of OTC cough/cold ingredients can be accurately assessed in a pediatric population
You may also be interested in...
Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture
Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture
Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture